Tarsus Pharmaceuticals (TARS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.43
- Estimate
- -$0.20
- Surprise
- -119.4%
- Revenue (period 2026-06-30)
- $173.9M
- Score at report (before → after)
- 6.4 → 6.4/10
Revenue source: xbrl.
How the report landed
Tarsus Pharmaceuticals (TARS) reported a wider loss than forecast — adjusted EPS of -$0.43 against the -$0.20 estimate (a 119.4% shortfall). TrendMatrix's engine moved from Buy (Wait) (6.4/10) to Hold at 6.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates TARS Sell at 6.3/10.
2 of the last 4 quarters beat the estimate; this quarter's -119.4% surprise compares with a -505.7% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Product: XDEMVY
- Concentration risk — Supplier: contract manufacturer in Europe
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $77.08
- Price target
- $84.97
- Stop
- $71.68
- Upside to target
- +10.2%
- Reward-to-risk
- 1.0:1
Model outputs from TrendMatrix’s engine as of 2026-09-23 — shown for context, not personalized investment advice.
TARS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.61B
- P/E (fwd)
- 31.9
- 52-week range
- $53.89–$91.53
- Off 52-week high
- 15.8%
- RSI (14)
- 54
- Volume vs avg
- 0.66×
- Score today
- 6.3/10